RBC Capital Maintains Sector Perform on Adverum Biotechnologies, Lowers Price Target to $2
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has maintained a 'Sector Perform' rating on Adverum Biotechnologies (NASDAQ:ADVM) but lowered the price target from $3 to $2.
March 19, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
RBC Capital has maintained its 'Sector Perform' rating on Adverum Biotechnologies but reduced the price target from $3 to $2.
The reduction in price target by RBC Capital, a notable financial institution, could lead to a negative perception among investors regarding ADVM's future performance, potentially causing a short-term decrease in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100